title: ALERT: mix-ups between conventional and lipid formulations of amphotericin B can be extremely dangerous.
abstract: In this column, the authors review Amphotericin B incidents reported Although amphotericin B may be less commonly used today because to ISMP Canada. In particular, we focus on incidents reported to have of alternative antifungal agents available, incident reports suggest resulted in patient harm due to mix-ups between the conventional there continues to be a need to alert practitioners to the different (non-lipid)formulation and lipid formulations of amphotericin B. formulations, and to implement system safety strategies.
authors.affiliation: Institute for Safe Medication Practices Canada. ckoczmara@ismp-canada.org
authors.forename: Christine
authors.initials: C
authors.lastname: Koczmara
authors.forename: Heather
authors.initials: H
authors.lastname: Richardson
authors.forename: Sylvia
authors.initials: S
authors.lastname: Hyland
authors.forename: Carol S Y
authors.initials: CS
authors.lastname: Lee
authors.forename: Nicky
authors.initials: N
authors.lastname: Hillebrand
mesh_terms: D000666:Amphotericin B / Q000009:adverse effects* / Q000737:chemistry*; D000935:Antifungal Agents / Q000009:adverse effects* / Q000737:chemistry*; D002170:Canada; D002626:Chemistry, Pharmaceutical; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D008508:Medication Errors / Q000706:statistics & numerical data*
chemical_list: D000935:Antifungal Agents; D008055:Lipids; D000666:Amphotericin B